Join
Live feed
·
PRReleasevia Quantisnow
XORTX Therapeutics Inc. logo

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

ByQuantisnow·Wall Street's wire, on your screen.
XRTX· XORTX Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track XRTX (XORTX Therapeutics Inc.) and more on Quantisnow.